NEW YORK (GenomeWeb) – The Stanley Center at the Broad Institute has received a promise of $650 million from philanthropist Ted Stanley to fund genomic research of psychiatric disorders in order to eventually identify and develop molecularly targeted drugs.

According to the Broad Institute, Stanley's new commitment to his namesake institute will consist of annual gifts during his lifetime followed by a bequest, totaling about $650 million. Taking prior gifts into account, Stanley's support of the Broad totals more than $825 million, the institute said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
18
Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.